ReviewExploration (Beijing, China)2025
Harnessing Biomarker Activatable Probes for Early Stratification and Timely Assessment of Therapeutic Efficacy in Cancer.
Review in Exploration (Beijing, China), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Review
- Natural Selection-Guided ACE2-Targeted Molecular Imaging: A New Paradigm for PET Tracer Development.Chemical & biomedical imaging · 2026Article
- Nanodelivery of Traditional Chinese Medicine Monomers: An Emerging Strategy to Reprogram the Immunosuppressive Tumor Microenvironment.International journal of nanomedicine · 2026Review
- CGRP at the Neuroimmune Interface: Regulator of Host Defense, Tumor Immunity, and Tissue Homeostasis.Research (Washington, D.C.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advancements in early stratification and timely evaluation of therapeutic effects have revolutionized the ability to assess curative outcomes promptly. The separation between diagnosis/treatment and timely assessment of treatment response, along with delays in evaluating therapy efficacy, are significant contributors to treatment failures. Traditional approaches for evaluating curative effects face challenges posed by tumor heterogeneity and resistance, making it challenging to determine the effectiveness of a given therapeutic regimen at an early stage in clinical practice. However, molecular imaging using activatable probes has overcome these obstacles and transformed the field by shifting focus towards developing functional probes for visualizing tumors as well as enabling early stratification or timely evaluation of therapy effects. In this article, we emphasize the importance of diverse activatable molecular imaging probes and provide insights into early stratification or timely evaluation of various therapies' effects. Finally, we discuss the challenges faced in this field and propose future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.